LivaNova Raises Full-Year Guidance, Secures Key FDA Approval for Sleep Apnea Device
LIVN sits 65% above its 52-week low of $35 on elevated volume (1.8× avg).
Summary
LivaNova PLC reported robust first-quarter 2026 results, with revenue increasing 14.3% on a reported basis. The company significantly raised its full-year 2026 revenue growth guidance by 100 basis points to 7.0%-8.0% (constant-currency) and adjusted diluted EPS guidance by $0.05 at the midpoint to $4.20-$4.30. This positive financial update was bolstered by the crucial news of receiving U.S. FDA premarket approval for its aura6000 System to treat moderate to severe obstructive sleep apnea. This approval marks a significant product development milestone, positioning LivaNova to enter a high-growth, high-margin market with a differentiated technology. The raised guidance and new market entry are strong indicators of improved operational performance and future growth prospects, following a 2025 net loss primarily due to a one-time liability. Traders will closely watch the commercial launch and market penetration of the aura6000 System.
At the time of this announcement, LIVN was trading at $57.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $35.00 to $71.92. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.